{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T02:47:39Z","timestamp":1784256459367,"version":"3.55.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T00:00:00Z","timestamp":1546214400000},"content-version":"vor","delay-in-days":364,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2018]]},"DOI":"10.6061\/clinics\/2018\/e756s","type":"journal-article","created":{"date-parts":[[2018,12,2]],"date-time":"2018-12-02T06:37:12Z","timestamp":1543732632000},"page":"e756s","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"S1","title":["Primary malignant tumors of the adrenal glands"],"prefix":"10.1016","volume":"73","author":[{"given":"Madson Q","family":"Almeida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao Evangelista","family":"Bezerra-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berenice B","family":"Mendon\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Claudia","family":"Latronico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Candida B V","family":"Fragoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.6061\/clinics\/2018\/e756s_bib1","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0467","article-title":"Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors","volume":"175","author":"Fassnacht","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"10.6061\/clinics\/2018\/e756s_bib2","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1210\/jc.2013-3020","article-title":"Update in adrenocortical carcinoma","volume":"98","author":"Fassnacht","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.6061\/clinics\/2018\/e756s_bib3","first-page":"1317","article-title":"Extensive personal experience: adrenocortical tumors","volume":"82","author":"Latronico","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.6061\/clinics\/2018\/e756s_bib4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.mce.2011.09.040","article-title":"Differences in the molecular mechanisms of adrenocortical tumorigenesis between children and adults","volume":"351","author":"Faria","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"10.6061\/clinics\/2018\/e756s_bib5","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev"},{"issue":"6","key":"10.6061\/clinics\/2018\/e756s_bib6","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.6061\/clinics\/2018\/e756s_bib7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0022-3476(75)80484-7","article-title":"Incidence of malignant tumors in U. S. children","volume":"86","author":"Young","year":"1975","journal-title":"J Pediatr"},{"key":"10.6061\/clinics\/2018\/e756s_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fcell.2015.00045","article-title":"Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment","volume":"3","author":"Lib\u00e9","year":"2015","journal-title":"Front Cell Dev Biol"},{"issue":"10","key":"10.6061\/clinics\/2018\/e756s_bib9","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1210\/jcem.86.10.7957","article-title":"An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors","volume":"86","author":"Latronico","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"26","key":"10.6061\/clinics\/2018\/e756s_bib10","doi-asserted-by":"crossref","first-page":"22724","DOI":"10.18632\/oncotarget.4261","article-title":"Low DICER1 expression is associated with poor clinical outcome in adrenocortical carcinoma","volume":"6","author":"de Sousa","year":"2015","journal-title":"Oncotarget"},{"issue":"5","key":"10.6061\/clinics\/2018\/e756s_bib11","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1590\/S0004-27302004000500009","article-title":"Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors","volume":"48","author":"Pinto","year":"2004","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"4","key":"10.6061\/clinics\/2018\/e756s_bib12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<711::AID-CNCR1>3.0.CO;2-W","article-title":"Adrenocortical carcinoma: clinical and laboratory observations","volume":"88","author":"Wajchenberg","year":"2000","journal-title":"Cancer"},{"issue":"4","key":"10.6061\/clinics\/2018\/e756s_bib13","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1159\/000345489","article-title":"Adrenocortical carcinoma: clinicopathological features, prognostic factors and outcome","volume":"90","author":"Keskin","year":"2013","journal-title":"Urol Int"},{"issue":"5","key":"10.6061\/clinics\/2018\/e756s_bib14","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1634\/theoncologist.2007-0243","article-title":"Molecular markers and the pathogenesis of adrenocortical cancer","volume":"13","author":"Soon","year":"2008","journal-title":"Oncologist"},{"issue":"18","key":"10.6061\/clinics\/2018\/e756s_bib15","first-page":"5358","article-title":"A cancer family syndrome in twenty-four kindreds","volume":"48","author":"Li","year":"1988","journal-title":"Cancer Res"},{"issue":"3","key":"10.6061\/clinics\/2018\/e756s_bib16","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1158\/1078-0432.CCR-06-2085","article-title":"Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity","volume":"13","author":"Lib\u00e0","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.6061\/clinics\/2018\/e756s_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1677\/jme.0.0230023","article-title":"Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line","volume":"23","author":"Logi\u00e9","year":"1999","journal-title":"J Mol Endocrinol"},{"issue":"17","key":"10.6061\/clinics\/2018\/e756s_bib18","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1101\/gad.9.17.2079","article-title":"An enhancer deletion affects both H19 and Igf2 expression","volume":"9","author":"Leighton","year":"1995","journal-title":"Genes Dev"},{"issue":"3","key":"10.6061\/clinics\/2018\/e756s_bib19","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ajmg.c.30267","article-title":"Beckwith-Wiedemann syndrome","volume":"154C","author":"Choufani","year":"2010","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"7","key":"10.6061\/clinics\/2018\/e756s_bib20","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1200\/JCO.2008.18.5678","article-title":"Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival","volume":"27","author":"de Reyni\u00e0s","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.6061\/clinics\/2018\/e756s_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1530\/EJE-11-0806","article-title":"Combined expression of BUB1B, DLGAP5, and PINK1 as predictors of poor outcome in adrenocortical tumors: validation in a Brazilian cohort of adult and pediatric patients","volume":"166","author":"Fragoso","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 7","key":"10.6061\/clinics\/2018\/e756s_bib22","doi-asserted-by":"crossref","first-page":"vii 131","DOI":"10.1093\/annonc\/mds231","article-title":"Adrenal cancer: ESMO Guidelines Working Group. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Berruti","year":"2012","journal-title":"Ann Oncol"},{"issue":"4","key":"10.6061\/clinics\/2018\/e756s_bib23","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.6061\/clinics\/2018\/e756s_bib24","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00000478-198903000-00004","article-title":"Pathologic features of prognostic significance in adrenocortical carcinoma","volume":"13","author":"Weiss","year":"1989","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.6061\/clinics\/2018\/e756s_bib25","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1097\/00000478-200212000-00009","article-title":"Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors","volume":"26","author":"Aubert","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.6061\/clinics\/2018\/e756s_bib26","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.humpath.2009.03.010","article-title":"The Weiss system for evaluating adrenocortical neoplasms: 25 years later","volume":"40","author":"Lau","year":"2009","journal-title":"Hum Pathol"},{"issue":"3","key":"10.6061\/clinics\/2018\/e756s_bib27","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1210\/jc.2014-3182","article-title":"Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection","volume":"100","author":"Beuschlein","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.6061\/clinics\/2018\/e756s_bib28","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdv329","article-title":"ENSAT network. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study","volume":"26","author":"Lib\u00e9","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"10.6061\/clinics\/2018\/e756s_bib29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1210\/jc.2012-2559","article-title":"German Adrenocortical Carcinoma Study Group. The role of surgery in the management of recurrent adrenocortical carcinoma","volume":"98","author":"Erdogan","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"23","key":"10.6061\/clinics\/2018\/e756s_bib30","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"Terzolo","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"10.6061\/clinics\/2018\/e756s_bib31","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1590\/s1677-5538.ibju.2017.0095","article-title":"Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best?","volume":"43","author":"Srougi","year":"2017","journal-title":"Int Braz J Urol"},{"issue":"11","key":"10.6061\/clinics\/2018\/e756s_bib32","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1210\/jc.2006-1007","article-title":"Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma","volume":"91","author":"Fassnacht","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.6061\/clinics\/2018\/e756s_bib33","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ijrobp.2015.01.007","article-title":"Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma","volume":"92","author":"Sabolch","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.6061\/clinics\/2018\/e756s_bib34","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1210\/jc.2012-2367","article-title":"A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma","volume":"98","author":"Habra","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.6061\/clinics\/2018\/e756s_bib35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/MED.0000000000000056","article-title":"Practical treatment using mitotane for adrenocortical carcinoma","volume":"21","author":"Terzolo","year":"2014","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"23","key":"10.6061\/clinics\/2018\/e756s_bib36","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"FIRM-ACT Study Group. Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.6061\/clinics\/2018\/e756s_bib37","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1186\/1471-2407-14-561","article-title":"A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers","volume":"14","author":"Halperin","year":"2014","journal-title":"BMC Cancer"},{"issue":"1","key":"10.6061\/clinics\/2018\/e756s_bib38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s12672-015-0241-2","article-title":"5th International ACC Symposium: Future and current therapeutic trials in adrenocortical carcinoma","volume":"7","author":"Hoff","year":"2016","journal-title":"Horm Cancer"},{"issue":"4","key":"10.6061\/clinics\/2018\/e756s_bib39","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.6061\/clinics\/2018\/e756s_bib40","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jmoldx.2017.04.009","article-title":"PheoSeq: a targeted next-generation sequencing assay for pheochromocytoma and paraganglioma diagnostics","volume":"19","author":"Curr\u00e1s-Freixes","year":"2017","journal-title":"J Mol Diagn"},{"issue":"2","key":"10.6061\/clinics\/2018\/e756s_bib41","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"issue":"4","key":"10.6061\/clinics\/2018\/e756s_bib42","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1210\/jc.2016-3829","article-title":"Characteristics of pediatric vs adult pheochromocytomas and paragangliomas","volume":"102","author":"Pamporaki","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.6061\/clinics\/2018\/e756s_bib43","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1210\/jc.2017-00992","article-title":"Malignant Pheochromocytoma and Paraganglioma: 272 patients over 55 years","volume":"102","author":"Hamidi","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.6061\/clinics\/2018\/e756s_bib44","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1245\/s10434-017-6074-1","article-title":"Clinical Predictors of malignancy in patients with pheochromocytoma and paraganglioma","volume":"24","author":"Dhir","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.6061\/clinics\/2018\/e756s_bib45","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1001\/jamaoncol.2017.0223","article-title":"Clinical characterization of the pheochromocytoma and paraganglioma susceptibility genes SDHA, TMEM127, MAX, and SDHAF2 for gene-informed prevention","volume":"3","author":"Bausch","year":"2017","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.6061\/clinics\/2018\/e756s_bib46","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2265.2008.03256.x","article-title":"123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation","volume":"69","author":"Bhatia","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"10.6061\/clinics\/2018\/e756s_bib47","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.2967\/jnumed.108.058701","article-title":"Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial","volume":"50","author":"Wiseman","year":"2009","journal-title":"J Nucl Med"},{"issue":"9","key":"10.6061\/clinics\/2018\/e756s_bib48","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/jnci\/djs188","article-title":"Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography","volume":"104","author":"Timmers","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"10.6061\/clinics\/2018\/e756s_bib49","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1200\/JCO.2006.09.6297","article-title":"Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma","volume":"25","author":"Timmers","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.6061\/clinics\/2018\/e756s_bib50","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1530\/EJE-14-0113","article-title":"Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma","volume":"171","author":"Baudin","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.6061\/clinics\/2018\/e756s_bib51","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1210\/jc.2012-4231","article-title":"Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma","volume":"98","author":"Ayala-Ramirez","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"25","key":"10.6061\/clinics\/2018\/e756s_bib52","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","article-title":"Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Gonias","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.6061\/clinics\/2018\/e756s_bib53","first-page":"334","article-title":"Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma","volume":"52","author":"Forrer","year":"2008","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"10","key":"10.6061\/clinics\/2018\/e756s_bib54","first-page":"1599","article-title":"Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma","volume":"47","author":"van Essen","year":"2006","journal-title":"J Nucl Med"},{"issue":"11","key":"10.6061\/clinics\/2018\/e756s_bib55","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1002\/cncr.26577","article-title":"Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience","volume":"118","author":"Ayala-Ramirez","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"10.6061\/clinics\/2018\/e756s_bib56","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12672-013-0133-2","article-title":"Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma","volume":"4","author":"Tanabe","year":"2013","journal-title":"Horm Cancer"},{"issue":"11","key":"10.6061\/clinics\/2018\/e756s_bib57","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","journal-title":"Int J Cancer"},{"issue":"9","key":"10.6061\/clinics\/2018\/e756s_bib58","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1055\/s-0029-1220687","article-title":"Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001)","volume":"41","author":"Druce","year":"2009","journal-title":"Horm Metab Res"},{"issue":"24","key":"10.6061\/clinics\/2018\/e756s_bib59","doi-asserted-by":"crossref","first-page":"6162","DOI":"10.1002\/cncr.27675","article-title":"Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas\/paragangliomas","volume":"118","author":"Oh","year":"2012","journal-title":"Cancer"},{"issue":"11","key":"10.6061\/clinics\/2018\/e756s_bib60","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1210\/jc.2012-2356","article-title":"Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas","volume":"97","author":"Ayala-Ramirez","year":"2012","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S180759322201153X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S180759322201153X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:05:23Z","timestamp":1761721523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S180759322201153X"},"secondary":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1807-59322018000200337&lng=en&nrm=iso&tlng=en","label":"SCIELO"},{"URL":"https:\/\/www.clinicsjournal.com\/article\/primary-malignant-tumors-of-the-adrenal-glands\/","label":"CLINICS"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":60,"alternative-id":["S180759322201153X"],"URL":"https:\/\/doi.org\/10.6061\/clinics\/2018\/e756s","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary malignant tumors of the adrenal glands","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.6061\/clinics\/2018\/e756s","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}],"article-number":"e756s"}}